Phase 2 N=92 PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19
SARS-CoV-2
Primary: Time to Sustained Alleviation or Resolution of COVID-19 Symptoms — 5.2; 6.1 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=6 An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis
Systemic Sclerosis
Primary: Change From Baseline in Modified Rodnan Total Skin Thickness Score (Total mRSS) at Week 24 — -9.5 scores on scale
Phase 2 N=79 Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia
Postherpetic Neuralgia
Primary: Change From Baseline (Week 2 of the Run-in Period) in Average Daily Pain Score (ADPS) — -1.62; -2.42 score on a scale — p=0.120
N/A N=47 Auricular Neurostimulation for Cyclic Vomiting Syndrome
Cyclic Vomiting Syndrome · Abdominal Migraine
Primary: Rhodes Index of Nausea, Vomiting & Retching (INVR) — 3.25; 5.80; 10.43; 0.75 score on a scale
N/A N=22 Feasibility Trial of a Stakeholder-enhanced Lay-navigator-delivered Intervention (ImPart-Multi)
Kidney Diseases · Cardiometabolic Risk Factors
Primary: Acceptability Interviews (Investigator Developed) — 3; 2; 2; 2 Participants
N/A N=27 Development of a Family-Based Transition Planning Program for Culturally-Diverse Youth on the Autism Spectrum
Autism Spectrum Disorder · Family Relations
Primary: Families FORWARD Program Acceptability Form — 52.00; 47.75 score on a scale
N/A N=92 Sleep IntervEntion as Symptom Treatment for ADHD
ADHD · Sleep · Adolescents
Primary: Sleep Architecture Objective TST [Total Sleep Time] Pre-test to Post-test — 8.11; 7.94; 8.03; 8.07 hours — p=.17
Phase 2 N=76 METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin
Colorectal Cancer Metastatic
Primary: Primary - Progression-free Survival (PFS) — 9.2; 9.2 Months of progression-free survival
Phase 2 N=25 Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma
Sarcoma
Primary: Number of Patients With Dose Limiting Toxicities. — 0; 1; 0 Participants
Phase 2 N=34 Immunologic Responses to a Live Attenuated Oral Cholera Vaccine
Cholera
Primary: Level of Antibody Titers in Serum — 76; 2671 Vibriocidal antibody titer
N/A N=57 The Effect Of Methylphenıdate Treatment On Neuroınflammatıon Levels In Chıldren Wıth Attentıon Defıcıt Hyperactıvıty Dısorder
Attention Deficit Disorder With Hyperactivity (ADHD)
Primary: Change in IL-6 Marker Level — 113.89; 103.45 ng/L — p=0.014
N/A N=1 LiveWell: Adapted DBT Skills Training for Metastatic Lung Cancer
Cancer Metastatic to Lung
Primary: Usability as Measured by the Total Number of Participants Who Complete the Study Questionnaires — 1 Participants
Phase 3 N=396 A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause
Vasomotor Symptoms Associated With Menopause · Hot Flashes
Primary: Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 4 (Assessed by Hot Flash Daily Diary [HFDD]). — 13.38; 14.26; -7.48; -4.37 Hot Flashes per day…
Phase 4 N=93 Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea In Non-HIV Patients
Chronic Diarrhea of Unknown Origin
Primary: Number of Participants With a 50 Percent Decrease in Mean Stool Count — 17 Participants
N/A N=160 Implementation a Data-to-Care Strategy to Improve HIV Continuum Outcomes for Out of Care People Living With HIV (PLWH) in Ukraine
HIV Infections
Primary: Number of Participants Engaged in HIV Care as Assessed by Number of Clinical Visits — 34; 58 Participants — p=<.001